Loading…
XLO
Xilio Therapeutics, Inc.
NASDAQ· Healthcare· Biotechnology· CUSIP 98422T209
$9.00+0.90%Price as of Aug 29, 18:39 UTC · updated once a day, after the close
Key metrics
- Market cap
- $59.22M
- P/E
- —
- Forward P/E
- —
- P/B
- 1.2x
- Dividend yield
- —
- Payout
- —
- EPS
- -$0.32
- ROE
- -55.03%
- Profit margin
- -34.06%
- Revenue growth
- +131.20%
- Beta
- -0.12
- 52-week high
- $12.74
- 52-week low
- $6.47
History
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▼ -96.2% over 5Y.
This stock has less than 5 years of price history — the answer would measure a shorter period than the one asked for.
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 5 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Year-end price | $8.96 | $13.37 | $7.70 | $37.66 | $224.00 | |
| P/S | — | 1.2x | 7.8x | — | — | — |
| P/B | 1.5x | 1.5x | 2.8x | 0.5x | 0.7x | 2.4x |
| EPS | -$4.19 | -$15.24 | -$38.92 | -$45.08 | -$189.28 |
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| INKTMiNK Therapeutics, Inc. | $11.43 | — | — | — | — | $58.32M |
| SRTSSensus Healthcare, Inc. | $3.52 | — | 1.6x | — | -34.83% | $57.95M |
| IMAImageneBio, Inc. | $5.34 | — | 0.4x | — | -82.68% | $60.74M |
| HYPDHyperion Defi Inc | $3.92 |
About the company
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies. The company's pipeline includes XTX501, a bispecific PD-1 / masked IL-2, for patients with metastatic non-small cell lung cancer; Efarindodekin alfa, an investigational, masked IL-12, that is in Phase 2 clinical trial for patients with advanced solid tumors; and Vilastobart, an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4 monoclonal antibody. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.
- 76
- Waltham, United States
Company description provided by Yahoo Finance.